Moreover, KCTD9 was highly expressed in hepatic NK cells obtained from HBV-ACLF patients compared with that in mild chronic hepatitis B (CHB) patients, indicating KCTD9 is a potential therapeutic target in HBV-ACLF patients [29]. Here, KCTD9 is linked to chronic hepatitis B virus infection.